| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia (NCT07623200) | Incyte Corporation | 2026-09-08 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease (NCT07559396) | Incyte Corporation | 2026-05-29 |
| A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment (NCT07559474) | Incyte Corporation | 2026-05-27 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (NCT07124078) | Incyte Corporation | 2026-05-20 |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms (NCT07441694) | Incyte Corporation | 2026-05-11 |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (NCT07522073) | Incyte Corporation | 2026-04-09 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants (NCT07448155) | Incyte Corporation | 2026-03-19 |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (NCT07284849) | Incyte Corporation | 2026-03-05 |
| Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07213973) | Incyte Corporation | 2026-02-02 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (NCT07195916) | Incyte Corporation | 2026-01-08 |
| Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders (NCT07104565) | Incyte Corporation | 2025-12-29 |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (NCT07214779) | Incyte Corporation | 2025-12-09 |
| Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants (NCT07218744) | Incyte Corporation | 2025-11-13 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo (NCT06804811) | Incyte Corporation | 2025-11-13 |
| Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa (NCT07049575) | Incyte Corporation | 2025-11-03 |
| Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants (NCT07039929) | Incyte Corporation | 2025-07-28 |
| A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants (NCT07018635) | Incyte Corporation | 2025-07-16 |
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors (NCT06873789) | Incyte Corporation | 2025-06-30 |
| A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants (NCT06934980) | Incyte Corporation | 2025-06-27 |
| A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD (NCT06843408) | Incyte Corporation | 2025-06-25 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (NCT06959225) | Incyte Corporation | 2025-06-23 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis (NCT06832618) | Incyte Corporation | 2025-06-17 |
| Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (NCT06958211) | Incyte Corporation | 2025-06-12 |
| A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (NCT06821542) | Incyte Corporation | 2025-06-04 |
| A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants (NCT06909162) | Incyte Corporation | 2025-05-05 |
| A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203) (NCT06615050) | Incyte Corporation | 2025-04-02 |
| A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06818812) | Incyte Corporation | 2025-03-27 |
| Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib (NCT06855498) | Incyte Corporation | 2025-02-28 |
| Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, & Food Effect of Oral INCB000631 to Healthy Adult Participants (NCT06775327) | Incyte Corporation | 2025-02-13 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo (NCT06548360) | Incyte Corporation | 2025-01-24 |
| A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (NCT06585774) | Incyte Corporation | 2025-01-21 |
| A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants (NCT06713590) | Incyte Corporation | 2025-01-14 |
| A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (NCT06388564) | Incyte Corporation | 2024-10-11 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) (NCT06516952) | Incyte Corporation | 2024-10-10 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) (NCT06516965) | Incyte Corporation | 2024-10-10 |
| A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants (NCT06555081) | Incyte Corporation | 2024-09-25 |
| A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants (NCT06505265) | Incyte Corporation | 2024-08-12 |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms (NCT06313593) | Incyte Corporation | 2024-08-08 |
| A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants (NCT06441318) | Incyte Corporation | 2024-07-12 |
| A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants (NCT06416800) | Incyte Corporation | 2024-06-19 |
| A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants (NCT06309394) | Incyte Corporation | 2024-05-15 |
| A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females (NCT06380205) | Incyte Corporation | 2024-05-07 |
| A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis (NCT06238817) | Incyte Corporation | 2024-04-26 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors (NCT05949632) | Incyte Corporation | 2024-04-16 |
| A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants. (NCT06310304) | Incyte Corporation | 2024-03-26 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant (NCT06213818) | Incyte Corporation | 2024-03-14 |
| A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream (NCT06213831) | Incyte Corporation | 2024-02-27 |
| A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06212999) | Incyte Corporation | 2024-01-30 |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (NCT06179160) | Incyte Corporation | 2024-01-04 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT06034002) | Incyte Corporation | 2023-12-04 |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) (NCT06113445) | Incyte Corporation | 2023-11-29 |
| A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) (NCT06113471) | Incyte Corporation | 2023-11-27 |
| A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive (NCT05879822) | Incyte Corporation | 2023-10-30 |
| A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma (NCT05888844) | Incyte Corporation | 2023-10-09 |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (NCT05936359) | Incyte Corporation | 2023-09-25 |
| Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population (NCT06259669) | Incyte Corporation | 2023-09-13 |
| Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors (NCT05909995) | Incyte Corporation | 2023-08-29 |
| Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease (NCT05919511) | Incyte Corporation | 2023-08-01 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria (NCT05936567) | Incyte Corporation | 2023-07-31 |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema (NCT05906628) | Incyte Corporation | 2023-07-31 |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (NCT05836324) | Incyte Corporation | 2023-07-24 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma (NCT05851443) | Incyte Corporation | 2023-07-11 |
| A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo (NCT05750823) | Incyte Corporation | 2023-04-11 |
| An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis (NCT06627335) | Incyte Corporation | 2023-03-27 |
| The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (NCT05696392) | Incyte Corporation | 2023-03-16 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (NCT05755438) | Incyte Corporation | 2023-03-10 |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (NCT05219864) | Incyte Corporation | 2023-01-31 |
| Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2 (NCT05233410) | Incyte Corporation | 2023-01-31 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis (NCT05624723) | Incyte Corporation | 2023-01-12 |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) (NCT04796922) | Incyte Corporation | 2022-12-30 |
| A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (NCT05620823) | Incyte Corporation | 2022-12-19 |
| A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment (NCT05624710) | Incyte Corporation | 2022-12-08 |
| Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (NCT05635838) | Incyte Corporation | 2022-12-07 |
| A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus (NCT05593432) | Incyte Corporation | 2022-11-23 |
| Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab (NCT06465433) | Incyte Corporation | 2022-11-08 |
| Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis (NCT05456529) | Incyte Corporation | 2022-09-01 |
| Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (NCT05222555) | Incyte Corporation | 2022-07-19 |
| Study of INCB123667 in Subjects With Advanced Solid Tumors (NCT05238922) | Incyte Corporation | 2022-07-05 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (NCT05267106) | Incyte Corporation | 2022-05-20 |
| To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva (NCT05090891) | Incyte Corporation | 2022-05-05 |
| A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo (NCT05247489) | Incyte Corporation | 2022-05-05 |
| Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (NCT05253807) | Incyte Corporation | 2022-04-29 |
| Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (NCT05073458) | Incyte Corporation | 2022-03-15 |
| A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT04849715) | Incyte Corporation | 2022-03-11 |
| A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550 (NCT05101369) | Incyte Corporation | 2022-01-21 |
| An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (NCT04586244) | Incyte Corporation | 2022-01-14 |
| Study of Ruxolitinib Cream in Children With Atopic Dermatitis (NCT05034822) | Incyte Corporation | 2021-12-16 |
| Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis (NCT05099445) | Incyte Corporation | 2021-12-14 |
| Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement (NCT05127421) | Incyte Corporation | 2021-11-10 |
| A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis (NCT05061693) | Incyte Corporation | 2021-11-04 |
| The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis (NCT04839380) | Incyte Corporation | 2021-10-12 |
| Study of INCA 0186 in Subjects With Advanced Solid Tumors (NCT04989387) | Incyte Corporation | 2021-10-04 |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (NCT04981795) | Incyte Corporation | 2021-09-20 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (NCT04809467) | Incyte Corporation | 2021-09-16 |
| To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma (NCT04582539) | Incyte Corporation | 2021-08-19 |
| A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) (NCT04921969) | Incyte Corporation | 2021-07-19 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) (NCT04629508) | Incyte Corporation | 2021-07-12 |
| The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. (NCT04949191) | Incyte Corporation | 2021-07-08 |
| A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA) (NCT04896385) | Incyte Corporation | 2021-06-23 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (NCT04551053) | Incyte Corporation | 2021-05-26 |